» Articles » PMID: 2896213

IL-4-induced Lymphokine-activated Killer Cells. Lytic Activity is Mediated by Phenotypically Distinct Natural Killer-like and T Cell-like Large Granular Lymphocytes

Overview
Journal J Immunol
Date 1988 May 15
PMID 2896213
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of the current study was to characterize lymphokine-activated killer (LAK) activity induced with IL-4/B cell stimulatory factor-1 and to compare IL-4-induced LAK activity with IL-2-induced LAK activity. Culture of murine lymphocytes with high concentrations of IL-4 induced nonspecific lytic activity against a wide variety of tumors. Lytic activity induced by IL-4 increased with increasing concentrations of IL-4 over the range of 1.0 to 25 ng/ml. The kinetics of LAK induction by IL-4 and IL-2 were similar; however, IL-4 was less effective than IL-2 in maintaining lytic activity for longer culture periods and provided lower viable cell yields than did IL-2. Similar to IL-2, IL-4 induced blastogenesis and the generation of large granular lymphocytes, all LAK activity observed was exclusively associated with the large granular lymphocyte fraction, and the cytolytic effector cells were heterogeneous in regards to cell surface phenotype. The majority of IL-4-induced lytic activity was associated with mutually exclusive NK-like (i.e., NK-1.1+ Lyt-2-) and T cell-like (i.e., NK-1.1- Lyt-2+) LAK cells. The precursors for each subset were distinct and expressed the asialo-GM1+ Lyt-2- and the asialo-GM1+ Lyt-2+ phenotypes, respectively. Although IL-4-induced LAK effector cells were morphologically and phenotypically similar to IL-2-induced LAK cells, IL-2 generated equivalent numbers of T cell-like and NK-like LAK cells, whereas IL-4 generated 3.5-fold more T cell-like LAK cells than NK-like LAK cells. It might eventually be possible to exploit the preferential activation of T cell-like LAK by IL-4 for therapeutic advantage.

Citing Articles

Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line.

Girgis E, Mahoney J, Darling-Reed S, Soliman M Oncol Lett. 2011; 1(3):473-479.

PMID: 21442015 PMC: 3062976. DOI: 10.3892/ol_00000083.


EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model.

Kim M, Chang H, Kim T, Lee S, Park J, Kim Y J Korean Med Sci. 2009; 24(3):474-80.

PMID: 19543512 PMC: 2698195. DOI: 10.3346/jkms.2009.24.3.474.


Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.

Peace D, Smith J, Chen W, You S, Cosand W, Blake J J Exp Med. 1994; 179(2):473-9.

PMID: 8294861 PMC: 2191373. DOI: 10.1084/jem.179.2.473.


Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.

Tunru I, Suzuki H, Kobayashi M Experientia. 1993; 49(1):76-9.

PMID: 7679079 DOI: 10.1007/BF01928795.


Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H Cancer Immunol Immunother. 1989; 29(1):63-6.

PMID: 2785001 PMC: 11038766. DOI: 10.1007/BF00199918.